Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 32 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

16%

5 trials in Phase 3/4

Results Transparency

36%

10 of 28 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

N/A
12(46.2%)
Phase 2
7(26.9%)
Phase 3
4(15.4%)
Phase 1
2(7.7%)
Phase 4
1(3.8%)
26Total
N/A(12)
Phase 2(7)
Phase 3(4)
Phase 1(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (32)

Showing 20 of 32 trials
NCT05075967Not ApplicableEnrolling By Invitation

Getting to Zero Among HHI MSM in the American South

Role: lead

NCT04860323Not ApplicableCompleted

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Role: collaborator

NCT06101342Phase 2Active Not Recruiting

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Role: collaborator

NCT04804072Not ApplicableCompleted

INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit

Role: lead

NCT07288190Phase 2Not Yet Recruiting

Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR

Role: lead

NCT04403880Completed

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19

Role: collaborator

NCT04742491Phase 2Completed

Pre-Exposure Prophylaxis for Transgender Women in the US and South America

Role: lead

NCT06200545Not ApplicableCompleted

Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Malawi

Role: lead

NCT06148584Not ApplicableCompleted

Testing a Barbershop-based HIV Prevention Initiative Among Men

Role: lead

NCT06101329Phase 2Active Not Recruiting

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Role: collaborator

NCT02732730Phase 4Completed

Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

Role: lead

NCT01808352Completed

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

Role: lead

NCT04801758Not ApplicableCompleted

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

Role: collaborator

NCT01152918Not ApplicableCompleted

Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies

Role: lead

NCT02935296Not ApplicableCompleted

Integrated Treatment and Prevention for People Who Inject Drugs

Role: lead

NCT03201510Completed

Feasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan Africa

Role: lead

NCT01327651Phase 2Completed

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

Role: lead

NCT02663219Not ApplicableCompleted

Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States

Role: lead

NCT01233531Phase 3Completed

Effects of Cash Transfer for the Prevention of HIV in Young South African Women

Role: lead

NCT01276600Phase 1Completed

Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers

Role: lead